Table 1 Clinicopathologic characteristics of patients according to subtypes
| Â | HR+ (N = 71) | HER2+ (N = 14) | TN (N = 25) | P value |
|---|---|---|---|---|
Clinical characteristics at initial diagnosis | ||||
Median age | 43.8 (30-69) | 49.5 (33-65) | 47.0 (24-77) | .398 A |
Initial stage | ||||
I | 9 (12.7%) | 1 (7.1%) | 2 (8.0%) | Â |
II | 23 (32.4%) | 4 (28.6%) | 11 (44.0%) | Â |
III | 11 (15.5%) | 2 (14.3%) | 2 (8.0%) | Â |
IV | 25 (35.2%) | 6 (42.9%) | 9 (36.0%) | .951 B |
unknown | 3 (4.2%) | 1 (7.1%) | 1 (4.0%) | Â |
Familial History | 16 (23.5%) | 4 (28.6%) | 7 (29.2%) | .829 B |
DFI after surgery (median) | 47.6 months | 40.6 months | 38.7 months | 0.231 by log-rank test |
Tumor characteristics | ||||
B-R.Gr. III (n = 69) | 17 (37.8%) | 2 (25.0%) | 14 (87.5%) | *.001 B |
P53 <5% (n = 93) | 32 (55.2%) | 7 (50.0%) | 9 (42.9%) | .621 B |
Ki 67 >50% (n = 25) | 5 (31.3%) | 0 (0%) | 6 (85.7%) | *.013 B |
Previous (neoadjuvant or adjuvant) treatments | ||||
Curative surgery. | 45 (63.4%) | 8 (57.1%) | 15 (60.0%) | .888 B |
Neoadju-CTx | 3 (4.2%) | 0 (0%) | 1 (4.0%) | .573 B |
Adjuvant CTx | 35 (49.3%) | 7 (50.0%) | 12 (48.0%) | .991 B |
Adjuvant doxorubicin | 6 (17.1%) | 1 (14.3%) | 0 (0%) | .048 B |
Adjuvant HormoTx | 43 (60.6%) | 0 | 0 | < 0.0001 B |
Distant Metastases | ||||
Lung | 49 (74.2%) | 11 (84.6%) | 15 (62.5%) | 0.316 |
Pleura | 41 (57.8%) | 8 (57.4%) | 10 (45.5%) | 0.216 |
Liver | 33 (52.4%) | 11 (84.6%) | 10 (45.5%) | 0.046 |
Brain | 11 (17.7%) | 3 (23.1%) | 6 (27.3%) | 0.629 |
Bone | 36 (50.7%) | 8 (57.1%) | 10 (40.0%) | 0.283 |
Skin | 14 (19.7%) | 1 (7.1%) | 9 (36%) | 0.081 |
Soft tissue | 22 (31.0%) | 1 (7.1%) | 6 (24.0%) | 0.120 |
Next treatment after AC chemotherapy | ||||
Median number of CTx (range) | 3 (0-11) | 2 (0-8) | 1 (0-7) | 0.006 |
Number of patients with HormoTx (%) | 17 (24%) | 0 | 0 | 0.001 |
Number of patients with trastuzumab Tx (%) | 5 (7.0%) | 4 (28.6%) | 0 | 0.009 |